Thu, Aug 1, 9:13 PM (88 days ago)
Lumos Pharma, Inc. filed a Form 8-K with the SEC on August 1, 2024, to report its second-quarter financial results and operational updates. The company, headquartered in Austin, Texas, issued a press release and a financial results presentation for the quarter ending June 30, 2024. These documents were attached as Exhibits 99.1 and 99.2, respectively. The report, signed by CEO Richard J. Hawkins, includes updates on clinical developments and financial performance but does not detail specific amounts. The filing is intended to provide transparency and is not considered filed for purposes of Section 18 of the Securities Exchange Act.